Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy

Kairos Pharma, Ltd. ( (KAPA) ) has shared an announcement.

On March 2, 2026, Kairos Pharma, Ltd. entered into a binding term sheet to acquire from privately held Celyn Therapeutics, Inc. the exclusive worldwide rights to CL-273, an investigational, reversible, wild-type-sparing pan-EGFR small-molecule inhibitor for EGFR-mutant non-small cell lung cancer. The deal covers development, manufacturing, commercialization and related intellectual property, tangible assets, contractual rights and regulatory rights tied to CL-273.

Under the agreed terms, Celyn will receive Kairos Pharma equity equal to 16.5% of the company on a fully diluted basis at closing, a $15 million milestone payment upon FDA NDA or BLA submission paid in a mix of cash and shares, and a 2% royalty on U.S. net revenues for the life of the relevant intellectual property. Closing is contingent on customary conditions, including shareholder approvals for both companies, the absence of a material adverse effect, and any required clearance from NYSE American.

CL-273 was discovered using an AI-driven drug discovery platform and is designed to spare wild-type EGFR while targeting resistance mutations that emerge with existing EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. The addressable EGFR-mutant lung cancer market is estimated at about $16.2 billion in 2026, with EGFR mutations seen in roughly 10–15% of Western NSCLC cases and up to 50% in Asian populations.

Management framed the transaction as a pivotal, value-accretive expansion of Kairos Pharma’s oncology pipeline and a step toward building a next-generation portfolio of targeted therapies for EGFR-mutant lung cancer. Backing of CL-273’s originator Celyn by investors OrbiMed and Torrey Pines Investment, and the involvement of D. Boral Capital, LLC as sole financial advisor, further signal an effort by Kairos Pharma to align itself with established oncology-focused investors and strengthen its position in the competitive lung cancer market.

The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.

More about Kairos Pharma, Ltd.

Kairos Pharma, Ltd., based in Los Angeles and listed on NYSE American under the ticker KAPA, is a clinical-stage biopharmaceutical company focused on oncology therapeutics. The company uses structural biology to address drug resistance and immune suppression in cancer, with its lead antibody candidate ENV-105 in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for non-small cell lung cancer.

ENV-105 targets CD105, a protein associated with resistance and relapse to standard cancer therapies, with the aim of restoring treatment effectiveness across multiple tumor types. As of March 2, 2026, none of Kairos Pharma’s product candidates, including ENV-105, have been approved as safe or effective by the U.S. Food and Drug Administration or other regulators.

Average Trading Volume: 539,078

Technical Sentiment Signal: Sell

Current Market Cap: $12.61M

See more insights into KAPA stock on TipRanks’ Stock Analysis page.